MetaStat Inc
OTC:MTST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
MetaStat Inc
OTC:MTST
|
US |
|
Iteknik Holding Corp
OTC:ITKH
|
US |
|
K
|
Kothari Products Ltd
NSE:KOTHARIPRO
|
IN |
|
I
|
IPB Petroleum Ltd
ASX:IPB
|
AU |
|
Cohort PLC
LSE:CHRT
|
UK |
|
W
|
Wuxi Double Elephant Micro Fibre Material Co Ltd
SZSE:002395
|
CN |
|
Eterna Therapeutics Inc
NASDAQ:ERNA
|
US |
|
Rocketfuel Blockchain Inc
OTC:RKFL
|
US |
|
A
|
Alfonsino SpA
MIL:ALFO
|
IT |
|
Guangzhou KDT Machinery Co Ltd
SZSE:002833
|
CN |
|
FKS Multi Agro Tbk PT
IDX:FISH
|
ID |
MetaStat Inc
MetaStat, Inc. engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Boston, Massachusetts. The company went IPO on 2008-02-13. The firm's platform technologies are based on the identification of a pathway for the development of metastatic disease in epithelial-based solid tumors. The company is developing two driver-based diagnostic product lines: MetaSite Breast and MenaCalc. Its MetaSite Breast and MenaCalc diagnostic product candidates are designed for patients based on their individual risk of metastasis. The MetaSite Breast test is applicable for early stage invasive breast cancer patients. The MenaCalc platform is a tissue-based quantitative immunofluorescence (QIF) assay applicable to a range of epithelial-based cancers, including breast, lung, colorectal and prostate.
MetaStat, Inc. engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Boston, Massachusetts. The company went IPO on 2008-02-13. The firm's platform technologies are based on the identification of a pathway for the development of metastatic disease in epithelial-based solid tumors. The company is developing two driver-based diagnostic product lines: MetaSite Breast and MenaCalc. Its MetaSite Breast and MenaCalc diagnostic product candidates are designed for patients based on their individual risk of metastasis. The MetaSite Breast test is applicable for early stage invasive breast cancer patients. The MenaCalc platform is a tissue-based quantitative immunofluorescence (QIF) assay applicable to a range of epithelial-based cancers, including breast, lung, colorectal and prostate.
